Last reviewed · How we verify
NCT06051162
HPI Effect in Robotic Urological Surgery on AKI
NA trial testing BP management with HPI guidance in Prostate Cancer in 124 participants. Status unknown.
31 July 2024
Quick facts
| Lead sponsor | Ewha Womans University Mokdong Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 124 |
| Start date | 7 November 2023 |
| Primary completion | 31 July 2024 |
| Estimated completion | 31 July 2024 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- BP management with HPI guidance
Conditions studied
- Prostate Cancer — all drugs for Prostate Cancer →
- Renal Cancer — all drugs for Renal Cancer →
- Urologic Diseases — all drugs for Urologic Diseases →
Sponsor
Ewha Womans University Mokdong Hospital
Who can join
19 and older, any sex, with Prostate Cancer or Renal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
It is a single-center randomized controlled trial that aims to figure out the effect of the hypotension prediction index (HPI) on the prevention of acute kidney injury (AKI) after robot-assisted urological surgery. The primary hypothesis is that HPI software guidance prevents postoperative AKI by reducing the duration and severity of intraoperative hypotension (IOH).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06051162
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of BP management with HPI guidance
Trials testing the same drug.
- NCT04994639 — Hypotension Prediction Effect on AKI · NA · completed
Other recruiting trials for Prostate Cancer
Currently open trials in the same condition.
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
- NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
- NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
Other Ewha Womans University Mokdong Hospital trials
Trials by the same sponsor.
- NCT07496281 — OPTIA-AF Trial: Rhythm-Guided Antithrombotic Strategy After AF Ablation · Phase 4 · not yet recruiting
- NCT07497893 — FENOX Trial (Comparative Effectiveness of Fexuprazan Co-therapy in Patients Receiving Non-Vitamin K Antagonist Oral Anti · NA · not yet recruiting
- NCT06929897 — PVI Alone vs PVI With Posterior Wall Isolation for Pulse-Field Ablation in Persistent AF · NA · not yet recruiting
- NCT06889818 — Korean Joint Registry for Alzheimer's Treatment and Diagnostics (JOY-ALZ) · recruiting
- NCT05725187 — Prospective Validation Study of AI-based Prediction Algorithm for the Prediction of Paroxysmal Atrial Fibrillation · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06051162 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ewha Womans University Mokdong Hospital
- Last refreshed: 15 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06051162.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing